Eli Lilly (LLY) and Company announced that the European Commission has granted marketing authorization for Kisunla for the treatment of early symptomatic Alzheimer’s disease in adults with mild cognitive impairment as well as those with mild dementia stages of AD with confirmed amyloid pathology who are apolipoprotein E heterozygotes or non-carriers.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly (LLY) to Build $6.5 Billion Manufacturing Plant in Texas
- FDA approves Lilly’s Inluriyo for type of advanced or metastatic breast cancer
- Eli Lilly (LLY) Stops Trial of Drug Meant to Preserve Muscle Mass
- Eli Lilly’s New Study on LY3537031: A Potential Game-Changer?
- Eli Lilly’s Phase 1 Study of LY3876602: Key Insights for Investors